Allosteric cross-talk in chromatin can mediate drug-drug synergy
- Journal:
- Nature Communications
- Published:
- DOI:
- 10.1038/ncomms14860
- Affiliations:
- 3
- Authors:
- 8
Research Highlight
Off-site workers prove effective
© Photography by ZhangXun/Moment/Getty
The binding of an anticancer agent to the proteins that spool around DNA helps an unrelated drug — one used to treat rheumatoid arthritis — to bind more efficiently in cancer cells.
Together, the two drugs kill many more ovarian cancer cells than either agent alone.
A team co-led by researchers at Nanyang Technological University showed that the therapeutic synergy results from a ‘domino’ model of drug attachment to the histone proteins that package DNA. After the anticancer drug RAPTA-T binds the DNA, it changes the shape of the histone in a way that makes it easier for the antirheumatic agent auranofin to bind at a distant site, different to the one where it normally acts.
While this kind of ‘off-site’ activity often leads to problematic side effects, in this case, it enhances the drugs’ destructive power against tumours.
References
- Nature Communications 8, 14860 (2017). doi: 10.1038/ncomms14860
Institutions | Authors | Share |
---|---|---|
Nanyang Technological University (NTU), Singapore | 0.50 | |
Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland | 0.50 |